RANDOMIZED PHASE II STUDY OF AZD6244 (MITOGEN-ACTIVATED PROTEIN KINASE INHIBITOR) MEK-INHIBITOR WITH ERLOTINIB IN KRAS WILD TYPE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AND A RANDOMIZED PHASE II STUDY OF AZD6244 WITH ERLOTINIB IN MUTANT KRAS ADVA...: